The global rise in obesity and type 2 diabetes is fueling an epidemic of MASLD and MASH, now recognized as the leading cause ...

Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program.1 Lilly also ...

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

New research into GLP-1 receptor has opened a realm of new treatment possibilities to treat opioid use disorder (OUD), a ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Medical treatments, including jabs used for weight loss, are monitored in part using the Medicines and Healthcare products ...

Drugs approved for diabetes and obesity might be useful for the treatment of cognitive and mental health disorders, according ...

Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent study.

Data submitted to the UK drugs regulator show a total of 82 deaths related to glucagon-like peptide-1 receptor agonists, the class of drugs used for weight loss and type 2 diabetes. Data from the ...

MillaF // Shutterstock Are Ozempic side effects more common in females? Ozempic (semaglutide) is a prescription medication ...

Recent research found that weight loss drugs like Ozempic may be contributing to a national trend of thyroid cancer ...

Terns announced that management will participate in the TD Cowen 45th Annual Healthcare Conference taking place from March 3-5, 2025 in Boston ...